Indirect Analysis of First-Line Therapy for Advanced Non-Small-Cell Lung Cancer with Activating Mutations in a Japanese Population

References

• Bray F , FerlayJ, SoerjomataramI, SiegalRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Guadagno A . World Lung Cancer Day 2019: facts & figures. Cure: Cancer Updates, Research & Education (2019). https://www.curetoday.com/view/world-lung-cancer-day-2019-facts--figures
   Google Scholar
• Shi YK , WangL, HanBet al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a Phase III, open-label, randomized study. Ann. Oncol.28(10), 2443–2450 (2017).
   PubMed Web of Science ®Google Scholar
• Wu YL , ZhouC, LiamCKet al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the Phase III, randomized, open-label, ENSURE study. Ann. Oncol.26(9), 1883–1889 (2015).
   PubMed Web of Science ®Google Scholar
• Gower A , WangY, GiacconeG. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J. Mol. Med. (Berl.)92(7), 697–707 (2014).
   PubMed Web of Science ®Google Scholar
• Han B , TjulandinS, HagiwaraKet al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study. Lung Cancer113, 37–44 (2017).
   PubMed Web of Science ®Google Scholar
• Liu L , LiuJ, ShaoDet al. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients. Cancer Sci.108(12), 2487–2494 (2017).
   PubMed Web of Science ®Google Scholar
• Yatabe Y , KerrKM, UtomoAet al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J. Thorac. Oncol.10(3), 438–445 (2015).
   PubMed Web of Science ®Google Scholar
• Stewart E , TanSZ, LiuG, TasoMS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl. Lung Cancer Res.4(1), 67–81 (2015).
   PubMed Web of Science ®Google Scholar
• Maemondo M , InoueA, KobayashiKet al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.362(25), 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , MoritaS, YatabeYet al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase III trial. Lancet Oncol.11(2), 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, ThongprasertSet al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Rosell R , CarcerenyE, GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase III trial. Lancet Oncol.13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Sequist LV , YangJC, YamamotoNet al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.31(27), 3327–3334 (2013).
   PubMed Web of Science ®Google Scholar
• Wu YL , ZhouC, HuCPet al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase III trial. Lancet Oncol.15(2), 213–222 (2014).
   PubMed Web of Science ®Google Scholar
• Zhou C , WuYL, ChenGet al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase III study. Lancet Oncol.12(8), 735–742 (2011).
   PubMed Web of Science ®Google Scholar
• Akamatsu H , NinomiyaK, KenmotsuHet al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int. J. Clin. Oncol.24(7), 731–770 (2019).
   PubMed Web of Science ®Google Scholar
• Turke AB , ZejnullahuK, WuYLet al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell17(1), 77–88 (2010).
   PubMed Web of Science ®Google Scholar
• Cabanero M , SanghaT, SeffieldBSet al. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Curr. Oncol.24(2), 111–119 (2017).
   PubMed Web of Science ®Google Scholar
• Mok T , CarboneD, HirschF. IASLC Atlas of EGFR testing in lung cancer. IASLC (2017). https://www.iaslc.org/Portals/0/egfr_atlas_lo-res.pdf?ver=2019-06-06-153729-323
   Google Scholar
• Wang S , CangS, LiuD. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J. Hematol. Oncol.9, 34 (2016).
   PubMed Web of Science ®Google Scholar
• Wu YL , ChengY, ZhouXet al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, Phase III trial. Lancet Oncol.18(11), 1454–1466 (2017).
   PubMed Web of Science ®Google Scholar
• Soria JC , OheY, VansteenkisteJet al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med.378(2), 113–125 (2018).
   PubMed Web of Science ®Google Scholar
• Nakagawa K , OhyanagiF, KatoTet al. P3. 01-072 dacomitinib versus gefitinib for first-line treatment of advanced EGFR+ NSCLC in Japanese patients (ARCHER 1050). J. Thoracic Oncol.12(11), S2229–S2230 (2017).
   Google Scholar
• Ohe Y , ImamuraF, NogamiNet al. Osimertinib versus standard-of-care EGFR TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J. Clin. Oncol.49(1), 29–36 (2019).
   PubMed Web of Science ®Google Scholar
• Goss G , TsaiC, ShepherdFAet al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, Phase II study. Lancet Oncol.17(12), 1643–1652 (2016).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, AhnMJet al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med.376(7), 629–640 (2017).
   PubMed Web of Science ®Google Scholar
• Yang JC , AhnMJ, KimDWet al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension component. J. Clin. Oncol.35(12), 1288–1296 (2017).
   PubMed Web of Science ®Google Scholar
• Franek J , CappelleriJC, Larkin-KaiserKA, WilnerKD, SandinR. Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer. Future Oncol.15(24), 2857–2871 (2019).
   PubMed Web of Science ®Google Scholar
• University of York Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Centre for Reviews and Dissemination (2009). https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf
   Google Scholar
• Hutton B , SalantiG, CaldwellDMet al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med.162(11), 777–784 (2015).
   PubMed Web of Science ®Google Scholar
• Moher D , LibertiA, TetzlaffJ, AltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med.151(4), 264–269 (2009).
   PubMed Web of Science ®Google Scholar
• Pao W , MillerVA, KrisMG. ‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin. Cancer Biol.14(1), 33–40 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaRet al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Higgins JP , SterneJA, SovavicJet al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database of Systematic Reviews10(Suppl. 1), 29–31 (2016).
   Google Scholar
• Jansen JP , FleurenceR, DevineBet al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health14(4), 417–428 (2011).
   PubMed Web of Science ®Google Scholar
• Phillippo D , AdesT, DiasS, PalmerS, AbramsKR, WeltonN. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. (2016). https://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2017/05/Population-adjustment-TSD-FINAL.pdf
   Google Scholar
• Plummer M . rjags: bayesian graphical models using MCMC. R Package Version 4.6 (2016). https://cran.r-project.org/web/packages/rjags/rjags.pdf
   Google Scholar
• Spiegelhalter DTA , BestN, GilksWet al. Bayesian inference using Gibbs sampling manual (version ii). MRC Biostatistics Unit, Cambridge, UK (1996).
   Google Scholar
• Brooks SP , GelmanA. General methods for monitoring convergence of iterative simulations. J. Comput. Graph. Stat.7(4), 434–455 (1998).
   Web of Science ®Google Scholar
• Dias S , WeltonNJ, SuttonAJ, AdesAE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. (2011). www.ncbi.nlm.nih.gov/books/NBK310366/pdf/BookshelfNBK310366.pdf
   Google Scholar
• Chaimani A , HigginsJP, MavridisD, SpyridonosP, SalantiG. Graphical tools for network meta-analysis in STATA. PLoS ONE8(10), e76654 (2013).
   PubMed Web of Science ®Google Scholar
• Guyot P , AdesAE, OuwensMJ, WeltonNJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol.12, 9 (2012).
   PubMed Web of Science ®Google Scholar
• Bormann I . Digitizeit software. Germany. https://www.digitizeit.de/
   Google Scholar
• Seto T , KatoT, NishioMet al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, Phase II study. Lancet Oncol.15(11), 1236–1244 (2014).
   PubMed Web of Science ®Google Scholar
• Batson S , MitchellSA, WindischT, DamonteE, MunkVC, ReguartN. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco. Targets Ther.10, 2473–2482 (2017).
   PubMed Web of Science ®Google Scholar
• Furuya N , FukuharaT, SaitoHet al. Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: nEJ026. J. Clin. Oncol.36(15), 9006 (2018).
   Web of Science ®Google Scholar
• Inoue A , KobayashiK, MaemondoMet al. Updated overall survival results from a randomized Phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann. Oncol.24(1), 54–59 (2013).
   PubMed Web of Science ®Google Scholar
• Kato T , SetoT, NishioMet al. Erlotinib plus bevacizumab Phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results. Drug Saf.41(2), 229–237 (2018).
   PubMed Web of Science ®Google Scholar
• Oizumi S , KobayashiK, InoueAet al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist17(6), 863–870 (2012).
   PubMed Web of Science ®Google Scholar
• Yamamoto N , SetoT, NishioMet al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small-cell lung cancer (NSCLC): survival follow-up results of JO25567. J. Clin. Oncol.36(15), 9007 (2018).
   Web of Science ®Google Scholar
• Zhang S , MaoXD, WangHT, CaiF, XuJ. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. BMJ Open6(6), e011714 (2016).
   PubMed Web of Science ®Google Scholar
• Kato T , YoshiokaH, OkamotoIet al. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci.106(9), 1202–1211 (2015).
   PubMed Web of Science ®Google Scholar
• Saito H , FukuharaT, FuruyaNet al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, Phase III trial. Lancet Oncol.20(5), 625–635 (2019).
   PubMed Web of Science ®Google Scholar
• Yang JJ , ZhouQ, YanHHet al. A Phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br. J. Cancer116(5), 568–574 (2017).
   PubMed Web of Science ®Google Scholar
• Urata Y , KatakamiN, MoritaSet al. Randomized Phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J. Clin. Oncol.34(27), 3248–3257 (2016).
   PubMed Web of Science ®Google Scholar
• Nishio M , KatoT, NihoSet al. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Cancer Sci.111(5), 1724–1738 (2020).
   PubMed Web of Science ®Google Scholar
• Gibson AJW , D’SilvaA, ElegbedeAAet al. Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer. Asia Pac. J. Clin. Oncol.15(6), 343–352 (2019).
   PubMed Web of Science ®Google Scholar
• Lee CK , DaviesL, WuYLet al. Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. J. Natl Cancer Inst.109(6), djw279 (2017).
   Google Scholar
• Lin JZ , MaSK, WuSX, YuSH, LiXY. A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: should osimertinib be the first-line treatment?Medicine (Baltimore)97(30), e11569 (2018).
   PubMed Web of Science ®Google Scholar
• Wang L , CaoY, RenMet al. Sex differences in hazard ratio during drug treatment of non-small-cell lung cancer in major clinical trials: a focused data review and meta-analysis. Clin. Ther.39(1), 34–54 (2017).
   PubMed Web of Science ®Google Scholar
• Higgins JP . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].Cochrane Training, ON, Ottawa (2011).
   Google Scholar
• Park K , TanEH, O’BryneKet al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a Phase IIB, open-label, randomised controlled trial. Lancet Oncol.17(5), 577–589 (2016).
   PubMed Web of Science ®Google Scholar
• Patil VM , NoronhaV, JoshiAet al. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open2(1), e000168 (2017).
   PubMed Web of Science ®Google Scholar
• Wu YL , YangJ, ZhouCet al. PL03. 05: BRAIN: a phase III trial comparing WBI and chemotherapy with icotinib in NSCLC with brain metastases harboring EGFR mutations (CTONG 1201). J. Thoracic Oncol.12(1), S6 (2017).
   Web of Science ®Google Scholar
• Han B , JinB, ChuTet al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial. Int. J. Cancer141(6), 1249–1256 (2017).
   PubMed Web of Science ®Google Scholar